IL23R +2199A/C polymorphism is associated with decreased risk of certain subtypes of gastric cancer in Chinese: A case-control study

Cancer Epidemiology

Volumn 35, Issue 2, 2011, Pages 165-169

  Chen, Bin ^a,e   Zeng, Zhirong ^a   Xu, Lixia ^a   Wu, Xiaoqin ^a   Yu, Jun ^b   Xue, Ling ^c   Hao, Yuantao ^c   Wang, Yiming ^d   Sung, Joseph J Y ^b   Chen, Minhu ^a   Hu, Pinjin ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c SUN YAT SEN UNIVERSITY   (China)

^d SUN YAT SEN UNIVERSITY   (China)

^e GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Clinicopathological characteristics; Gastric cancer; Interleukin 23 receptor; Polymorphism

Indexed keywords

GENOMIC DNA; INTERLEUKIN 23 RECEPTOR;

ADULT; ARTICLE; CANCER RISK; CANCER SURVIVAL; CHINESE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROGNOSIS; STOMACH CANCER;

EID: 79953103017     PISSN: 18777821     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canep.2010.08.006     Document Type: Article

References (20)

1. Iwakura Y., Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest 2006, 116:1218-1222.
2. Zhang Z., Kyttaris V.C., Tsokos G.C. The role of IL-23/IL-17 axis in lupus nephritis. J Immunol 2009, 183:3160-3169.
3. van der Fits L., Mourits S., Voerman J.S., Kant M., Boon L., Laman J.D., et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 2009, 182:5836-5845.
4. Maloy K.J. The Interleukin-23/Interleukin-17 axis in intestinal inflammation. J Intern Med 2008, 263:584-590.
5. Oppmann B., Lesley R., Blom B., Timans J.C., Xu Y., Hunte B., et al. Novel p19 protein engages IL-12p40 to form a cytokine. IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000, 13:715-725.
6. Cho J.H., Weaver C.T. The genetics of inflammatory bowel disease. Gastroenterology 2007, 133:1327-1339.
7. Duerr R.H., Taylor K.D., Brant S.R., Rioux J.D., Silverberg M.S., Daly M.J., et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006, 314:1461-1463.
8. Farago B., Magyari L., Safrany E., Csongei V., Jaromi L., Horvatovich K., et al. Functional variants of interleukin-23 receptor gene confer risk for rheumatoid arthritis but not for systemic sclerosis. Ann Rheum Dis 2008, 67:248-250.
9. Rueda B., Orozco G., Raya E., Fernandez-Sueiro J.L., Mulero J., Blanco F.J., et al. The IL23R Arg381Gln non-synonymous polymorphism confers susceptibility to ankylosing spondylitis. Ann Rheum Dis 2008, 67:1451-1454.
10. Huber A.K., Jacobson E.M., Jazdzewski K., Concepcion E.S., Tomer Y. Interleukin (IL)-23 receptor is a major susceptibility gene for Graves' ophthalmopathy: the IL-23/T-helper 17 axis extends to thyroid autoimmunity. J Clin Endocrinol Metab 2008, 93:1077-1081.
11. Chen Y., Zhou B., Peng Y., Wang Y., Li C., Ding X., et al. Interleukin-23 receptor gene polymorphisms is associated with dilated cardiomyopathy in Chinese Han population. Tissue Antigens 2009, 73:330-334.
12. Siewert J.R., Stein H.J. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 1998, 85:1457-1459.
13. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand 1965, 64:31-49.
14. World Health Organization Classification of Tumours. Pathology and genetics of tumours of the digestive system 2000, IARC Press, Lyon, France. S.R. Hamilton, L.A. Aaltonen (Eds.).
15. Correa P. A human model of gastric carcinogenesis. Cancer Res 1988, 48:3554-3560.
16. Caruso R., Pallone F., Monteleone G. Emerging role of IL-23/IL-17 axis in H pylori-associated pathology. World J Gastroenterol 2007, 13:5547-5551.
17. Carneiro F., Seixas M., Sobrinho-Simoes M. New elements for an updated classification of the carcinomas of the stomach. Pathol Res Pract 1995, 191:571-584.
18. Langowski J.L., Zhang X., Wu L., Mattson J.D., Chen T., Smith K., et al. IL-23 promotes tumour incidence and growth. Nature 2006, 442:461-465.
19. Zhang Z., Zhou B., Zhang J., Chen Y., Lai T., Yan L., et al. Association of interleukin-23 receptor gene polymorphisms with risk of ovarian cancer. Cancer Genet Cytogenet 2010, 196:146-152.
20. Langowski J.L., Kastelein R.A., Oft M. Swords into plowshares: IL-23 repurposes tumor immune surveillance. Trends Immunol 2007, 28:207-212.